Clinical Trial

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Name: A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias — clinical trial record (NCT07491172)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.

Protocol Amendment History 1 change

notable Trial sites expanded: 18 -> 21 locations 2026-07-21

Trial Details

NCT Number	NCT07491172
Lead Sponsor	CRISPR Therapeutics AG
Conditions	Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG) +2 more
Enrollment	90 participants
Start Date	2024-06-21
Primary Completion	2027-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-23